SCHEMBL217714

SCHEMBL217714

CC(C)(C)[Si](C)(C)OCc1cc(-c2ccc3nc(-c4cnc5ccccc5c4)cn3c2)cs1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 15/20 0.37
ALDH1A1 P00352 4/20 0.37
ALDH1A2 O94788 1/20 0.37
SLC2A1 P11166 1/20 0.36
NR4A2 P43354 1/20 0.34
KCNH2 Q12809 1/20 0.34
PDGFRB P09619 2/20 0.33
PDGFRA P16234 2/20 0.33
ADORA2A P29274 1/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16266166 0.84 ALDH1A3 (0.33) ALDH1A3ALDH1A1ALDH1A2SLC2A1NR4A2
SCHEMBL217708 0.83 ALDH1A3 (0.42) ALDH1A3ALDH1A1ALDH1A2SLC2A1NR4A2
Hydrochloric Acid SCHEMBL218759 0.82 ALDH1A3 (0.41) ALDH1A3ALDH1A1ALDH1A2SLC2A1NR4A2
SCHEMBL216407 0.78 NR4A2 (0.34) ALDH1A3ALDH1A1NR4A2KCNH2RAB9A
SCHEMBL3411468 0.71 NR4A2 (0.67) ALDH1A3ALDH1A1ALDH1A2SLC2A1NR4A2
SCHEMBL3432955 0.69 NR4A2 (0.65) ALDH1A3ALDH1A1ALDH1A2SLC2A1NR4A2
SCHEMBL2735667 0.69 DYRK1A (0.44) ALDH1A1KCNH2
Hydrochloric Acid SCHEMBL6522828 0.68 NR4A2 (0.64) ALDH1A3ALDH1A1ALDH1A2SLC2A1NR4A2
SCHEMBL3435794 0.68 NR4A2 (0.52) ALDH1A3ALDH1A1ALDH1A2SLC2A1NR4A2
SCHEMBL219585 0.68 ALDH1A3 (0.61) ALDH1A3ALDH1A1ALDH1A2SLC2A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598166-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2013-12-03 US disclosed
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-03-01 US disclosed
US-8088765-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US disclosed
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262804-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-aventis (FR) 2010-12-22 EP disclosed
WO-2009144392-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 ALDH1A3 2936/4885ALDH1A1 765/4885ALDH1A2 1616/4885
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 ALDH1A3 2936/4885ALDH1A1 765/4885ALDH1A2 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.